{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "SGMT",
  "name": "Sagimet Biosciences Inc. Series A",
  "url": "https://orbyd.app/dossiers/SGMT/",
  "json_url": "https://orbyd.app/dossiers/SGMT.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "April denifanstat/acne breakout round-tripped to the $6.00 Series A offering floor; SGMT bases near $7 (last close $7.06, 2026-06-26) with no trend. Dermatology pivot (China NMPA acne NDA accepted Dec 2025, US IND due mid-2026) is real but decelerated to saturated, and no dated binary sits inside 30 days — a wait-for-re-acceleration name, not a fresh momentum entry.",
  "invalidation_trigger": "A weekly close below $6.00 loses the April Series A offering floor and turns the round-trip into a fresh downtrend; combined with the derm/MASH theme confirming saturated and the China NMPA acne decision still undated, that removes the last re-acceleration catalyst.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-05-01",
  "invalidation_fired": true,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "MASH combo optionality validated by resmetirom/Rezdiffra (MDGL) — UK MHRA authorization 2026-06-03; EASL 2026 combo Phase 1 named Best of EASL.",
    "Clinical-stage, pre-revenue: near-term risk is clinical/regulatory binary, not quarterly prints. Next financials est. ~Aug 2026 (Q2 update).",
    "April 2026 offering: 29.17M Series A shares @ $6.00 (~$175M gross), priced 2026-04-27, nearly doubled float to 61.75M sh. $6.00 is the structural floor and de-facto clearing level.",
    "China NMPA denifanstat acne NDA accepted Dec 2025 (partner Ascletis) — highest-impact near-term binary but UNDATED; no PDUFA-style decision date.",
    "US acne IND filing targeted mid-2026 enables an H2 2026 Phase 3 start — procedural, not a data readout. Watch for slippage past the window without an update.",
    "Beta 3.44 microcap; April spike was retail-velocity-driven and has faded. Carries retail-squeeze flush risk in any XBI risk-off despite emergent-narrative classification.",
    "MASH mechanism validated externally: FASCINATE-2 Phase 2b met all endpoints; combo Phase 1 'Best of EASL' 2026-05-27; resmetirom (MDGL/Rezdiffra) UK MHRA authorization 2026-06-03.",
    "2026-06-12 annual meeting was governance-only and has passed — not a tradeable catalyst."
  ],
  "body_markdown": "## Current Thesis\nThe late-April narrative-momentum breakout has fully round-tripped, and SGMT is digesting near the $6.00 Series A offering floor rather than trending. The last confirmed close was $7.06 (2026-06-26), inside the $6.00–$8.50 band that has governed the tape since the 2026-04-27 raise, and no catalyst has arrived in the weeks since to break it either way. The leg an investor would buy is the dermatology pivot — denifanstat for moderate-to-severe acne, where the China Phase 3 met every endpoint (June 2025) and the NMPA accepted the NDA (December 2025) — layered onto MASH combo optionality. The program is funded through 2028, but the narrative has decelerated: the April retail-velocity surge has bled out, the theme reads saturated, and the nearest event is a soft \"mid-2026\" US acne IND filing that clears the way for a trial start without producing any data. At current levels this is a hold-the-floor, wait-for-re-acceleration name, not a fresh momentum entry.\n\n## Bull Case\n- China Phase 3 acne (partner Ascletis) hit all primary and secondary endpoints (June 2025); the China NMPA accepted the denifanstat acne NDA (December 2025) — a live approval-and-commercialization path already inside the regulatory system.\n- The May 2026 strategic pivot to dermatology concentrates spend on the most de-risked asset;\n- Balance sheet funded through 2028 after the ~$175M gross raise (priced 2026-04-27) — no financing overhang into the next clinical inflection.\n- Sell-side is uniformly bullish and far above spot: consensus Strong Buy, average target ~$26.88 (range $12–$32). Canaccord Buy $49 (2026-05-04), Rodman & Renshaw Buy $28, Clear Street Buy $28, Guggenheim Buy $25 (2026-04-29), TD Cowen Buy $21. The lowest target is ~70% over the last print.\n- MASH mechanism is validating externally: FASCINATE-2 Phase 2b met all primary endpoints (F2/F3, week 52); the denifanstat/resmetirom combo Phase 1 was named \"Best of EASL\" at EASL 2026 (2026-05-27); and resmetirom (Madrigal's Rezdiffra) won UK MHRA authorization for MASH on 2026-06-03.\n\n## Bear Case\n- The round-trip is finished: the entire late-April move from ~$8.50 back to the $6–$7 shelf is gone, and price is basing at the offering floor with no trend to lean on. An entry here buys the post-mania fade.\n- Supply overhang pins the tape. The 2026-04-27 deal sold 29.17M Series A shares at $6.00, nearly doubling the float to 61.75M shares; that freshly-issued stock anchors price toward the $6.00 clearing level until it is absorbed.\n- Catalyst dead air. The US Phase 3 acne start and the F4 MASH combo Phase 2 are H2 2026 trial START dates that gate enrollment, with no data attached; the one genuine binary — China NMPA acne approval — carries no decision date.\n- Conviction is drifting even among bulls: Guggenheim cut its target to $25 (2026-04-29) and Clear Street to $28 from $37, softer marks from desks paid to like the name.\n- The risk profile is unforgiving: beta 3.44, thin float, and an April spike that was retail-velocity-driven. Any small-cap-biotech risk-off flushes this harder than the tape, and the crowd that drove the pop has already left.\n\n## Setup & Price Structure\n- Reference structure (last confirmed close $7.06, 2026-06-26): the working range is a $6.00 floor to a ~$8.50 pivot. Absent a new catalyst in the weeks since, the base is intact and unbroken in either direction.\n- $6.00 is the level that matters — both the April offering price and the de-facto clearing level for the doubled float. It has held through roughly two months of post-mania digestion.\n- ~$8.50 is the April breakout pivot; a volume reclaim of that shelf is what would turn a base into a fresh trend. Price sits ~18% above the floor and below the pivot — mid-range, no edge for a momentum buyer.\n- Microcap mechanics: beta 3.44, 61.75M shares outstanding post-raise. Moves are amplified both ways, and a base this quiet in a high-beta name usually resolves violently once a catalyst lands.\n\n## Catalyst Calendar (next 30 days)\n- US denifanstat acne IND filing — targeted \"mid-2026\" (~2026-07 to 2026-08, est.). Procedural and enabling; it unlocks the H2 2026 Phase 3 start but carries no data. Slippage past the window without an update would be a mild negative.\n- China NMPA denifanstat acne approval decision — NDA accepted December 2025, decision UNDATED. Highest-impact binary, but no calendar peg; it could land any week or not for months.\n- Q2 2026 financial update — estimated ~2026-08-12 (est.), at the edge of or just beyond the 30-day window. A cash-runway and pipeline-progress update for a pre-revenue name, immaterial as a price catalyst.\n- No dated, decision-grade binary sits inside the next 30 days.\n\n## What Would Change Our Mind\n- Bullish flip: a weekly close back above the ~$8.50 April pivot on expanding volume, ideally with MASH/derm peers breaking out in sympathy, or a dated China NMPA approval — any of which converts this from a dormant base into a live momentum entry worth sizing.\n- Bearish invalidation: a weekly close below $6.00 loses the offering floor and turns the round-trip into a fresh downtrend; paired with the theme confirming saturated, that removes the reason to keep it on the screen.\n- Fundamental re-rate: a firm US IND acceptance with a dated Phase 3 start, or a China acne approval, would reset the narrative clock and justify buying the reclaim rather than waiting on the base.\n\n## Correlation Notes\n- MASH read-through to MDGL (Madrigal): resmetirom's UK MHRA authorization (2026-06-03) de-risks the exact mechanism the denifanstat combo leans on; SGMT trades partly as a high-beta derivative of MASH sentiment.\n- Small-cap biotech beta (XBI): with beta 3.44 and a thin float, SGMT amplifies swings in biotech risk appetite; a broad XBI risk-off is the most likely trigger for a $6.00 floor test.\n- Ascletis (HK-listed partner): the China NMPA acne path runs through Ascletis, so its newsflow and any NMPA timeline signal is a direct read-through to SGMT's highest-impact binary.\n- FASN-inhibitor complex: denifanstat is a fatty-acid-synthase inhibitor, tying SGMT's read to metabolic/obesity and acne-dermatology peers rather than to broad large-cap pharma.",
  "first_seen": "2026-04-28",
  "last_analyzed": "2026-07-18T08:30:46+00:00",
  "last_synthesized": "2026-07-18",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}